LINE and International Vaccine Institute Release BT21 Donation Stickers to Promote Global Vaccination and Vaccine Development
2020.06.30 ALL
■ LINE FRIENDS’ BT21 characters featured in IVI sticker set to raise funds for child immunization initiatives and COVID-19 vaccine development
SEONGNAM, South Korea – June 30, 2020 – LINE Corporation today released a set of animated stickers together with the International Vaccine Institute (IVI) featuring LINE FRIENDS’ BT21 characters. With all sales proceeds going to IVI, this sticker initiative is one more demonstration of LINE’s mission of “Closing the Distance,” which includes taking actions to help people and improve their lives.
The animated sticker set, named “BT21: Protect You by LINE × IVI,” comes with 24 heartwarming stickers, designed to cheer users and remind them to stay healthy. The set is available for purchase globally (excluding certain markets) from June 30 until October 31, and is priced at 100 LINE Coins (or USD 1.99). Revenue from the stickers will go toward IVI’s child immunization initiatives and developing new vaccines, including COVID-19 vaccine development.
*Sticker download URL: https://line.me/S/sticker/17793
LINE Plus Corporation, the Korea-based subsidiary of LINE Corporation, earlier this year entered into a memorandum of understanding (MOU) with IVI. In addition to raising funds through the BT21 sticker set, the collaboration is leveraging LINE’s reach as a global mobile platform to promote the use of vaccines and increase rates of immunization around the world and give users access to reliable information about infectious diseases and vaccinations through an IVI Official Account (OA) in Indonesian, Thai and English.
An initiative of the United Nations Development Programme (UNDP), IVI is a non-profit international organization dedicated to vaccine research, development and delivery. The institute developed and completed tech transfer for the world’s first affordable oral cholera vaccine, entered phase III clinical trials for a novel typhoid conjugate vaccine, and recently announced that they will conduct a Phase I/II clinical trial for a new COVID-19 vaccine.
LINE has been implementing a variety of initiatives in response to the COVID-19 pandemic, and the agreement with IVI represents one more way LINE is bringing people closer to the information and services they need. For more information on LINE’s response to the pandemic, please visit the following page: https://linecorp.com/en/pr/news/global/2020/51
■About LINE Corporation
Based in Japan, LINE Corporation (NYSE:LN/TSE:3938) is dedicated to the mission of “Closing the Distance,” bringing together information, services and people. The LINE messaging app launched in June 2011 and since then has grown into a diverse, global ecosystem that includes AI technology, fintech and more.
■About LINE Plus Corporation
LINE Plus Corporation was established in March 2013 in South Korea as a subsidiary of LINE Corporation. It supports LINE’s global business development with programmers, designers, marketers, sales personnel and PR managers from around the world working together.
■About International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. IVI has 35 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden and India as state funders. Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, Group A Strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit www.ivi.int.